CA Patent

CA3120999C — CAPSULE FORMULATIONS

Assigned to Chemocentryx Inc · Expires 2025-04-01 · 1y expired

What this patent protects

This disclosure relates to solid-solution capsule formulations of Compound 1 and their preparation methods. The disclosure also relates to methods for treating individuals with a disease or disorder involving, or predisposed to, pathological activation of C5a receptors by adminis…

USPTO Abstract

This disclosure relates to solid-solution capsule formulations of Compound 1 and their preparation methods. The disclosure also relates to methods for treating individuals with a disease or disorder involving, or predisposed to, pathological activation of C5a receptors by administering an effective amount of one or more solid-solution capsules containing Compound 1. Unit-dose capsules containing specific amounts of Compound 1, and kits containing a solid-solution capsule containing Compound 1, are also described.

Drugs covered by this patent

Patent Metadata

Patent number
CA3120999C
Jurisdiction
CA
Classification
—
Expires
2025-04-01
Drug substance claim
No
Drug product claim
No
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.